WallStreetZenWallStreetZen

NASDAQ: CMPX
Compass Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for CMPX

Based on 2 analysts offering 12 month price targets for Compass Therapeutics Inc.
Min Forecast
$8.00+419.48%
Avg Forecast
$9.00+484.42%
Max Forecast
$10.00+549.35%

Should I buy or sell CMPX stock?

Based on 2 analysts offering ratings for Compass Therapeutics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CMPX stock forecasts and price targets.

CMPX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-08-12
lockedlocked$00.00+00.00%2024-08-07

1 of 1

Forecast return on equity

Is CMPX forecast to generate an efficient return?
Company
11.3%
Industry
-660.43%
Market
50.44%
CMPX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CMPX forecast to generate an efficient return on assets?
Company
10.61%
Industry
27.02%
CMPX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CMPX earnings per share forecast

What is CMPX's earnings per share in the next 3 years based on estimates from 7 analysts?
Avg 1 year Forecast
-$0.42
Avg 2 year Forecast
-$0.48
Avg 3 year Forecast
-$0.37

CMPX revenue forecast

What is CMPX's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$866.0k+1.88%
Avg 2 year Forecast
$18.7M+2,094.12%
Avg 3 year Forecast
$63.0M+7,311.53%
CMPX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CMPX revenue growth forecast

How is CMPX forecast to perform vs Biotechnology companies and vs the US market?
Company
316.08%
Industry
34.48%
Market
9.41%
CMPX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CMPX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CMPX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CMPX$1.54$9.00+484.42%Buy
CADL$6.57N/AN/A
RZLT$5.22$11.57+121.67%Strong Buy
PYXS$3.64$8.50+133.52%Strong Buy
FULC$3.44$11.50+234.30%Buy

Compass Therapeutics Stock Forecast FAQ

Is Compass Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: CMPX) stock is to Buy CMPX stock.

Out of 2 analysts, 0 (0%) are recommending CMPX as a Strong Buy, 2 (100%) are recommending CMPX as a Buy, 0 (0%) are recommending CMPX as a Hold, 0 (0%) are recommending CMPX as a Sell, and 0 (0%) are recommending CMPX as a Strong Sell.

If you're new to stock investing, here's how to buy Compass Therapeutics stock.

What is CMPX's earnings growth forecast for 2024-2026?

(NASDAQ: CMPX) Compass Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.25%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.75%.

Compass Therapeutics's earnings in 2024 is -$47,242,000.On average, 7 Wall Street analysts forecast CMPX's earnings for 2024 to be -$57,388,443, with the lowest CMPX earnings forecast at -$67,418,694, and the highest CMPX earnings forecast at -$53,659,777. On average, 7 Wall Street analysts forecast CMPX's earnings for 2025 to be -$66,042,802, with the lowest CMPX earnings forecast at -$100,440,095, and the highest CMPX earnings forecast at -$38,524,968.

In 2026, CMPX is forecast to generate -$50,453,949 in earnings, with the lowest earnings forecast at -$136,213,279 and the highest earnings forecast at $31,645,509.

What is CMPX's revenue growth forecast for 2024-2026?

(NASDAQ: CMPX) Compass Therapeutics's forecast annual revenue growth rate of 316.08% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.48%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.41%.

Compass Therapeutics's revenue in 2024 is $850,000.On average, 3 Wall Street analysts forecast CMPX's revenue for 2024 to be $119,152,222, with the lowest CMPX revenue forecast at $116,950,795, and the highest CMPX revenue forecast at $123,830,254. On average, 2 Wall Street analysts forecast CMPX's revenue for 2025 to be $2,566,038,039, with the lowest CMPX revenue forecast at $1,692,346,803, and the highest CMPX revenue forecast at $3,439,729,275.

In 2026, CMPX is forecast to generate $8,667,842,595 in revenue, with the lowest revenue forecast at $1,795,538,682 and the highest revenue forecast at $20,594,347,115.

What is CMPX's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: CMPX) forecast ROA is 10.61%, which is lower than the forecast US Biotechnology industry average of 27.02%.

What is CMPX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year CMPX price target, the average CMPX price target is $9.00, with the highest CMPX stock price forecast at $10.00 and the lowest CMPX stock price forecast at $8.00.

On average, Wall Street analysts predict that Compass Therapeutics's share price could reach $9.00 by Aug 12, 2025. The average Compass Therapeutics stock price prediction forecasts a potential upside of 484.42% from the current CMPX share price of $1.54.

What is CMPX's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: CMPX) Compass Therapeutics's current Earnings Per Share (EPS) is -$0.36. On average, analysts forecast that CMPX's EPS will be -$0.42 for 2024, with the lowest EPS forecast at -$0.49, and the highest EPS forecast at -$0.39. On average, analysts forecast that CMPX's EPS will be -$0.48 for 2025, with the lowest EPS forecast at -$0.73, and the highest EPS forecast at -$0.28. In 2026, CMPX's EPS is forecast to hit -$0.37 (min: -$0.99, max: $0.23).

What is CMPX's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: CMPX) forecast ROE is 11.3%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.